Cardiff Oncology, Inc.

    Jurisdiction
    United States
    LEI
    549300AHOLZBHHYFWP04
    ISIN
    US14147L1089 (CRDF)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    51 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    7 / 7

    Profile

    Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Read full profile

    Fundamentals

    Net revenue
    €465.71K
    Gross margin
    82.4%
    EBIT
    -€46.34M
    EBIT margin
    -9,950.9%
    Net income
    -€43.52M
    Net margin
    -9,345.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €281.47K -39.6% -€55.37M +27.2%
    €110.88K -60.6% -€78.10M +41.1%
    €341.18K +207.7% -€114.02M +46.0%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    PACE GARY W N/A +290K $2.45 +$710.50K

    Earnings Calls

    Earnings Calls

    Latest earnings call: May 2, 2024 (Q1 2024)

    Add to watchlist

    Notifications